| 7.41 0.11 (1.51%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.95 | 1-year : | 9.67 |
| Resists | First : | 7.66 | Second : | 8.27 |
| Pivot price | 7.06  |
|||
| Supports | First : | 6.66 | Second : | 5.54 |
| MAs | MA(5) : | 7.39 |
MA(20) : | 7.1 |
| MA(100) : | 6.81 |
MA(250) : | 9.48 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 55 |
D(3) : | 64.6 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 16.76 | Low : | 5.63 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DAWN ] has closed below upper band by 23.7%. Bollinger Bands are 8.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.46 - 7.49 | 7.49 - 7.52 |
| Low: | 7.05 - 7.09 | 7.09 - 7.12 |
| Close: | 7.34 - 7.41 | 7.41 - 7.47 |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Mon, 06 Oct 2025
Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last? - Yahoo Finance
Tue, 16 Sep 2025
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - MSN
Sat, 06 Sep 2025
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Held Back By Insufficient Growth Even After Shares Climb 30% - simplywall.st
Fri, 22 Aug 2025
Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Shares Lagging The Industry But So Is The Business - 富途牛牛
Thu, 07 Aug 2025
Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade) - Seeking Alpha
Wed, 06 Aug 2025
Day One Biopharma’s Earnings Call Highlights Growth and Strategy - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 102 (M) |
| Shares Float | 79 (M) |
| Held by Insiders | 16.9 (%) |
| Held by Institutions | 85.3 (%) |
| Shares Short | 11,220 (K) |
| Shares Short P.Month | 11,700 (K) |
| EPS | -0.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.5 |
| Profit Margin | -50.7 % |
| Operating Margin | -103.2 % |
| Return on Assets (ttm) | -15.2 % |
| Return on Equity (ttm) | -24.8 % |
| Qtrly Rev. Growth | 313.8 % |
| Gross Profit (p.s.) | 1.72 |
| Sales Per Share | 1.83 |
| EBITDA (p.s.) | -1.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -63 (M) |
| Levered Free Cash Flow | -144 (M) |
| PE Ratio | -8.33 |
| PEG Ratio | 0 |
| Price to Book value | 1.64 |
| Price to Sales | 4.04 |
| Price to Cash Flow | -12.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|